The role for aspirin in cardiovascular primary prevention remains controversial, with potential benefits limited by an increased bleeding risk.
D espite reductions in death from cardiovascular disease over the past few decades, rates of death from stroke and myocardial infarction have plateaued in the United States. 1 The health and economic burden of cardiovascular disease has triggered the Centers for Disease Control and Prevention and the Centers for Medicare & Medicaid Services to launch the Million Hearts 2022 initiative, aiming to prevent cardiovascular events through risk factor optimization. 2, 3 One target is to improve appropriate aspirin (acetylsalicylic acid) prescribing. The benefit of aspirin in the secondary prevention of stroke and myocardial infarction is well-established; however, its use in primary prevention remains controversial. 4 Clinical trials of aspirin in patients without cardiovascular disease have inconsistently demonstrated improvements in cardiovascular outcomes, 5, 6 with potential benefits countered by increased risks of clinically significant bleeding. 7 The uncertain role of aspirin in primary prevention of cardiovascular events is reflected in contrasting recommendations offered by guideline bodies. 8, 9 The overall effect of this uncertainty has been a decline in aspirin prescribing for primary prevention over the past 5 to 10 years. 1, 10 The purpose of this meta-analysis was to assess the association of aspirin use with cardiovascular events and bleeding events in populations without cardiovascular disease.
Methods
This article has been reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. 11 The protocol is available in Supplement 1.
Ethical approval was not required for this study.
Data Sources
A systematic search of PubMed and Embase was conducted on Cochrane Central Register of Controlled Trials (CENTRAL) from the earliest publication date available through November 1, 2018 (eMethods 1 in Supplement 2). The reference lists of included studies and meta-analyses identified in the search were screened for additional studies. After removal of duplicates, the titles and abstracts of the search results were screened for relevance by both authors. The full texts of the remaining results were individually assessed by both authors, independently, for inclusion based on predetermined criteria. The final list of included studies was decided on by discussion between authors, with full agreement required before inclusion. No disagreements required resolution by a third reviewer.
Study Selection
Trials were considered eligible if they (1) were a randomized clinical trial (RCT); (2) enrolled participants without known preexisting cardiovascular disease; (3) compared aspirin at any dose with no aspirin (defined as placebo or no treatment); (4) had a follow-up of at least 12 months; (5) enrolled over 1000 participants; (6) provided information on any of the prespecified primary and secondary cardiovascular outcomes, primary and secondary bleeding outcomes, or cancer outcomes; and (7) were published in the English language.
Data Extraction
Data were extracted using piloted forms, independently by both authors, and were transcribed into a dedicated database. The data extracted from each report included baseline participant characteristics, inclusion criteria, study drug and control treatment, follow-up duration, and end point data. Relevant subgroup data were extracted when available. The Antithrombotic Trialists' (ATT) Collaboration provided additional outcome data on individual studies included in their individual patient data meta-analysis. 4 Some event counts
were updated by the ATT Collaboration from the original publications because of reclassification of International Classification of Diseases codes, with updated counts used in this analysis. Secondary publications of original studies were included if they reported on relevant outcomes. Risk of bias assessment was done by the authors independently using the Cochrane Collaboration risk of bias tool across 5 domains (sequence generation, allocation concealment, blinding, detection bias, attrition bias, and reporting bias). No disagreements required resolution by a third reviewer. The Egger test was used to identify asymmetry of funnel plots for publication bias. 12 
Outcomes
The primary cardiovascular outcome was a composite of cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke. Secondary cardiovascular outcomes included allcause mortality, cardiovascular-related mortality, myocardial infarction, total stroke (ischemic, hemorrhagic, and unknown), and ischemic stroke. The primary bleeding outcome was major bleeding and was individually defined by studies. Secondary bleeding outcomes included intracranial bleeding (intracerebral, subarachnoid, and subdural) and major gastrointestinal bleeding.
Cardiovascular and bleeding outcome definitions used in studies were identified (eTable 1 in Supplement 2) and end point data were extracted with the aim to maintain consistency of definitions. For the primary cardiovascular outcome, stroke was defined as both ischemic and hemorrhagic for all studies except
The effect of aspirin on cancer incidence and mortality is uncertain, with meta-analyses yielding contrasting results 13, 14 and the Aspirin in Reducing Events in the Elderly (ASPREE) study demonstrating an increased risk of cancer mortality with aspirin. 15 In light of the uncertain evidence of aspirin on cancer outcomes generated from previous studies, incident cancer and cancer mortality were prespecified as exploratory outcomes.
Data Synthesis
A Bayesian meta-analysis was performed using the GeMTC package on R Software, version 3.4.1 (R Foundation for Statistical Computing). Analyses were performed using Markov chain Monte Carlo methods. 16 Fixed-effects or random-effects models were selected for each outcome based on the deviance information criterion, using the model with the smallest value 17 (eMethods 3 in Supplement 2). Between-study heterogeneity was assessed using the I 2 statistic. When deviance information criterion values were similar, the I 2 was used for model selection. Results are presented as hazard ratios (HRs) with 95% credible intervals (CrIs). For studies that reported event counts only, differences in follow-up duration between studies were incorporated using the trial patient-years follow-up to estimate HRs using Poisson likelihood and log link. 17 Relative risk, with 95% CIs, was calculated using frequentist pairwise meta-analysis. Absolute risk reductions (ARRs) and absolute risk increases (ARIs) were calculated by multiplying the control risk by the calculated relative risk and 95% CIs. Numbers needed to treat and harm were derived by dividing 1 by the calculated ARRs and ARIs, respectively.
Sensitivity analyses were performed restricted to aspirin dose (excluding total daily doses >100 mg), double-blind placebo-controlled studies, and studies published after 2000. The year 2000 was chosen to represent the modern era of cardiovascular primary prevention. Post hoc sensitivity analyses, excluding the ASCEND trial and studies that enrolled participants with asymptomatic peripheral arterial disease from the primary cardiovascular outcome analysis, were also conducted. All data were represented graphically with network and forest plots using R software, version 3.4.1 and Microsoft Excel.
Results

Study Search and Study Characteristics
The systematic search of articles published before November 1, 2018, identified 1385 articles, of which 21 articles reporting on 13 studies were included 5, 6, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] (eFigure 1 in Supplement 2; Table) . In total, 164 225 participants were enrolled, comprising 1 050 511 participant-years of followup. The median (interquartile range) duration of follow-up was 5.0 (4.7-6.7) years. The comparator treatment was placebo in 9 studies and no aspirin in 4 studies, while 6 studies used a factorial design ( having diabetes. The median study 10-year estimated cardiovascular event rate was 9.2% (range, 2.6%-15.9%).
Risk of Bias and Publication Bias
Of the 13 included studies, 9 were at low risk of bias and 4 were at high risk (eFigure 2 and eTable 2 in Supplement 2). There were 9 double-blind and 4 open-label studies, with the latter deemed high risk of bias. There was no evidence of publication bias for the primary outcome (Egger test: −0.47; P = .57) (eFigure 3 in Supplement 2). 
Primary Cardiovascular Outcome
Secondary Cardiovascular Outcomes
All-cause and cardiovascular mortality were reported in all 13 studies. 
Outcomes Across Population Cardiovascular Risk Range and in Participants With Diabetes
The estimated population 10-year risk of the primary composite cardiovascular outcome was less than 10% in 6 studies enrolling 112 566 participants (median, 6.8%; range, 2.6%-8.1%) 6, 18, 20, 23, 24, 26 and was at least 10% in 7 studies enrolling 50 383 participants (median, 12.7%; range, 10.2%-15.9%). 5, 19, 21, 22, 25, 27, 28 The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) study did not report on the primary outcome and trial 10-year risk was not estimated. 25 However, the 10-year myocardial infarction event rate (19.2%) justified its inclusion in the high-risk subgroup. The Women's Health Study reported subgroup data for patients with a 10-year cardiovascular risk of 10% or more, which was included in the high-risk subgroup.
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In studies in which the risk of the cardiovascular outcome was low, aspirin use was associated with reductions in the primary composite cardiovascular outcome (HR, 0.87 [95% CrI, 0.79-0.95]; ARR, 0.34% [95% CI, 0.14%-0.52%]; NNT, 297) compared with no aspirin (Figure 2 ;e T a b l e3i nSupplement 2). Aspirin was not associated with reductions in any of the secondary outcomes. Aspirin use was associated with increased risk of major bleeding (HR, 
Discussion
In this meta-analysis of 13 trials enrolling 164 225 participants without cardiovascular disease, aspirin use was associated with reductions in the composite cardiovascular outcome consisting of cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke. However, aspirin use was associated with an increased risk of major bleeding, intracranial bleeding, and major gastrointestinal bleeding with comparable absolute risk estimates. Aspirin use was associated with reductions in the primary cardiovascular composite outcome and increases in major bleeding risks in both low and high cardiovascular risk populations and in participants with diabetes. Compared with aspirin use in patients with established atherosclerotic cardiovascular disease, aspirin use for primary prevention has been controversial. This uncertainty has been reflected in contradictory guideline recommendations. 8, 9 The current study demonstrates that when considering the totality of evidence, cardiovascular benefits
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associated with aspirin were modest and equally balanced by major bleeding events. This study builds on previous meta-analyses through the inclusion of 3 studies that enrolled participants for whom uncertainty regarding the efficacy of aspirin for primary prevention existed. The Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) trial enrolled participants with moderate to high estimated cardiovascular risk, the ASCEND trial enrolled participants with diabetes, and the ASPREE trial enrolled older participants (older than 65 or 70 years of age, depending on ethnicity). It has been suggested that patients with substantially increased cardiovascular risk may benefit from preventive aspirin use. 9 The US Preventive Services Task Force recommends the initiation of low-dose aspirin in adults aged 50 to 69 years with a 10-year cardiovascular risk of 10% or more. 9 However, the use of cardiovascular risk scores tends to overestimate an individual's true risk, 32 with poor agreement between different cardiovascular risk calculators. 33 The difference in predicted and observed cardiovascular risk was demonstrated by the ARRIVE trial, in which moderate-risk participants (mean American College of Cardiology/American Heart Association 10-year atherosclerotic cardiovascular disease risk of 17.3%) had an observed event rate of less than 10%. 6 This study showed that when analysis was restricted to populations with observation-derived 10-year cardiovascular event rate estimates of 10% or more, aspirin use was associated with an absolute risk decrease of 0.51% (95% CI, 0.06%-0.93%) for the cardiovascular composite outcome, but an absolute risk increase of 0.64% (95% CI, 0.35%-0.97%) for major bleeding. The challenge of interpreting absolute risk across different outcomes lies in the interpretation of the severity of each outcome. The current study demonstrates that the absolute risk reduction for cardiovascular events and absolute risk increase for major bleeding associated with aspirin use were of similar magnitude. Aspirin use was not associated with a reduction in cardiovascular mortality, and deaths due to bleeding were rare. Consequently, the decision to use aspirin for primary prevention may need to be made on an individual basis, accounting for the patient's risk of bleeding and their views on the balance of risk vs benefit. 34 The role of additional measures to reduce the potential harms of long-term aspirin use is not clear from the present study. Coprescription of aspirin with a proton pump inhibitor (PPI) may limit the risk of significant gastrointestinal bleeding and, therefore, shift the risk-benefit ratio toward an overall benefit of aspirin use for primary prevention in patients without cardiovascular disease. 27 However, the use of PPIs was inconsistently reported in the studies included in this analysis. Furthermore, this strategy has not been adequately tested in RCTs and is of uncertain cost effectiveness.
28
The ASPREE study, which enrolled healthy older individuals (median age, 74), demonstrated an increased risk of death in patients randomized to receive aspirin, driven primarily by a 31% increased risk of cancer mortality. 15 This finding is in contrast to an individual patient data meta-analysis of primary and secondary prevention aspirin trials that demonstrated a 15% reduction in cancer mortality associated with aspirin use. 13 While the reduction in cancer mortality emerged after at least 5 years of follow-up, this result was not replicated in the ASCEND trial that followed up 15 480 participants with diabetes for a mean of 7.4 years. The findings of this study suggest that the association of aspirin with cancer outcomes is neutral, with no suggestion of harm or benefit from the available current evidence. Hazard Ratio (95% CrI) Cancer outcomes across all studies, in low and high cardiovascular risk populations, and in patients with diabetes. The absolute risk reductions and increases were calculated by multiplying the control event risk by the relative risk, and 95% CIs derived by frequentist meta-analysis (eFigure 4 in Supplement 2). Study heterogeneity was assessed using I 2 statistics. HR indicates hazard ratio; CrI indicates credible interval; CV indicates cardiovascular. Data for the JPAD, JPPP, and WHS trials were extracted from subsequent trial publications on cancer outcomes. [29] [30] [31] Data for the HOT, BDS, and PHS (cancer mortality) and the HOT, BDS, AAA, and POPADAD (incident cancer) trials were extracted from previous meta-analyses on cancer outcomes. 
Limitations
This study has several limitations. First, the inherent limitations of meta-analyses exist, including the availability and quality of reported data. 35 This was particularly apparent in the diabetes subgroup, in which cardiovascular and bleeding events were poorly reported in studies. Second, end point definitions between trials differed depending on contemporary consensus definitions, reflecting the long time frame and diagnostic advances encompassed by trials in this study. For the primary cardiovascular outcome, all studies except for ASCEND defined stroke events as including both ischemic and hemorrhagic etiologies. Post hoc sensitivity analysis excluding ASCEND did not alter the overall findings. Hemorrhagic stroke events could have been included as both a cardiovascular and a bleeding outcome. Third, the total daily doses of aspirin varied in studies from 50 mg to 500 mg, with the majority using doses from 75 mg to 100 mg daily. Doses greater than 100 mg daily are not representative of current clinical practice. Importantly, sensitivity analysis restricted to daily aspirin doses of 100 mg or less demonstrated similar results to the overall analysis, including an increased risk of major bleeding outcomes. Fourth, 8 trials began randomizing study participants over 20 years ago, with 3 trials initiating recruitment in the 1970s and 1980s. 19, 20, 22 Increasing adoption of additional primary prevention strategies, such as risk factor modification and development of public health initiatives, may limit the applicability of earlier studies to current practice. In studies published after 2000, aspirin was associated with reductions in the primary cardiovascular outcome and increases in all bleeding outcomes, but was no longer associated with reduced myocardial infarctions when only more contemporary studies were included.
Conclusions
In this meta-analysis, the use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding. This information may inform discussions with patients about aspirin for primary prevention of cardiovascular events and bleeding.
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The purpose of this meta-analysis was to assess the association of aspirin use with cardiovascular events and bleeding events in populations without cardiovascular disease.
Methods
Data Sources
A systematic search of PubMed and Embase was conducted on Cochrane Central Register of Controlled Trials (CENTRAL) from the earliest publication date available through November 1, 2018 (eMethods 1 in Supplement 2). The reference lists of included studies and meta-analyses identified in the search were screened for additional studies. After removal of duplicates, the titles and abstracts of the search results were screened for relevance by both authors. The full texts of the remaining results were individually assessed independently by both authors for inclusion based on predetermined criteria. The final list of included studies was decided on by discussion between authors, with full agreement required before inclusion. No disagreements required resolution by a third reviewer.
Study Selection
Trials were considered eligible if they (1) were a randomized clinical trial (RCT); (2) enrolled participants without known preexisting cardiovascular disease; (3) compared aspirin at any dose with no aspirin (defined as placebo or no treatment); (4) had a follow-up of at least 12 months; (5) enrolled over 1000 participants; (6) provided information on any of the prespecified primary and secondary cardiovascular outcomes, primary and secondary bleeding outcomes, or cancer outcomes; and (6) were published in the English language.
Data Extraction
Data were extracted using piloted forms, independently by both authors, and were transcribed into a dedicated database. The data extracted from each report included baseline participant characteristics, inclusion criteria, study drug and control treatment, follow-up duration, and end point data. Relevant subgroup data were extracted when available. The Antithrombotic Trialists' (ATT) Collaboration provided additional outcome data on individual studies included in their individual patient data meta-analysis. 4 Some event counts were updated by the ATT Collaboration from the original publications because of reclassification of International Classification of Diseases codes, with updated counts used in this analysis. Secondary publications of original studies were included if they reported on relevant outcomes. Risk of bias assessment was done by the authors in duplicate using the Cochrane Collaboration risk of bias tool across 5 domains (sequence generation, allocation concealment, blinding, detection bias, attrition bias, and reporting bias). No disagreements required resolution by a third reviewer. The Egger test was used to identify asymmetry of funnel plots for publication bias.
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Outcomes
Cardiovascular and bleeding outcome definitions used in studies were identified (eTable 1 in Supplement 2) and end point data were extracted with the aim to maintain consistency of definitions. For the primary cardiovascular outcome, stroke was defined as both ischemic and hemorrhagic
Key Points
Question What is the association of aspirin use with cardiovascular events and bleeding events in individuals without cardiovascular disease?
Findings In this meta-analysis of 13 trials with 164 225 participants without cardiovascular disease, aspirin use was associated with a lower risk of cardiovascular events, defined as cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (hazard ratio [HR], 0.89; absolute risk reduction, 0.38%) and an increased risk of major bleeding (HR, 1.43; absolute risk increase, 0.47%). 
Meaning
In individuals without cardiovascular disease, the use of aspirin was associated with a lower risk of cardiovascular events and an increased risk of major bleeding. Research Original Investigation Association of Aspirin Use for Primary Prevention of CVD With Cardiovascular Events and
Subgroup Analysis
Cardiovascular and bleeding outcomes were analyzed for study populations with low and high cardiovascular risk and in participants with diabetes. Cardiovascular risk subgroups were based at the trial level. The 10-year risk of the primary outcome was calculated by multiplying the annualized event rate for the primary outcome in the control group by 10 years (eMethods 2 in Supplement 2). A high cardiovascular risk was defined as an estimated 10-year risk of the primary outcome of at least 10%, and low cardiovascular risk was defined as an estimated 10-year risk of the primary outcome of less than 10%. 9 
Exploratory Cancer Outcomes
The effect of aspirin on cancer incidence and mortality is uncertain, with meta-analyses yielding contrasting results 13, 14 and the Aspirin in Reducing Events in the Elderly (ASPREE) study demonstrating an increased risk of cancer mortality with aspirin. 15 In light of the uncertain evidence of aspirin on cancer outcomes generated from previous studies, incident cancer and cancer mortality were prespecified as exploratory outcomes. Analysis was restricted to studies using aspirin at total daily doses of 100 mg or less.
Data Synthesis
Results
Study Search and Study Characteristics
The systematic search of articles published before November 1, 2018, identified 1385 articles, of which 21 articles reporting on 13 studies were included 5, 6, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] (eFigure 1 in Supplement 2; Table) . In total, 164 225 participants were enrolled, comprising 1 050 511 participant-years of follow-up. The median (interquartile range) duration of follow-up was 5.0 (4.7-6.7) years. The comparator treatment was placebo in 9 studies and no aspirin in 4 studies, while 6 studies used a factorial design (2 additionally tested vitamin E 
Risk of Bias and Publication Bias
Of the 13 included studies, 9 were at low risk of bias and 4 were at high risk (eFigure 2 and eTable 2 in Supplement 2). There were 9 double-blind and 4 open-label studies, with the latter deemed high risk of bias. There was no evidence of publication bias for the primary outcome (Egger test: −0.47; P =.57) (eFigure 3 in Supplement 2). 
Primary Cardiovascular Outcome
Secondary Cardiovascular Outcomes
All-cause and cardiovascular mortality were reported in all 13 studies. a Data are presented as mean (SD) unless otherwise specified.
b 10-Year risk of the primary cardiovascular outcome was calculated by multiplying the annualized event rate for the primary cardiovascular outcome in the control group by 10 years.
c 5085 participants were randomized in a 2x2 factorial design warfarin, aspirin, warfarin and aspirin, or placebo. 2545 were randomized to warfarin and excluded from analysis.
d Data reported as median (range).
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Bleeding Outcomes
Outcomes Across Population Cardiovascular Risk Range and in Participants With Diabetes
The estimated population 10-year risk of the primary composite cardiovascular outcome was less than 10% in 6 studies enrolling 112 566 participants (median, 6.8%; range, 2.6%-8.1%) 6, 18, 20, 23, 24, 26 and was at least 10% in 6 studies en- Participants with diabetes C Trials were deemed low or high risk if the 10-year cardiovascular risk for the primary cardiovascular outcome was less than 10% or greater than or equal to 10%, respectively. The composite cardiovascular (CV) outcome consisted of cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke.
Hazard ratios (HRs) and 95% credible intervals (CrIs) were calculated using Bayesian meta-analysis of trial level event counts. The absolute risk reductions and increases were calculated by multiplying the control event risk by the relative risk and 95% CIs were derived by Frequentist meta-analysis (eFigure 4 in Supplement 2). Study heterogeneity was assessed using I 2 statistics. CrIcredible interval; CV -cardiovascular; GI -gastrointestinal. (Figure 2 ; eTable 3 in Supplement 2). There was evidence of moderate heterogeneity for cardiovascular mortality in patients with diabetes (I 2 = 35%). Heterogeneity was low for all other outcomes in patients with diabetes (I 2 range, 0%-23%). Event rates and absolute risk differences for all outcomes are available in eTable 3 and eTable 5 in Supplement 2.
Sensitivity Analysis
Eleven studies (134 470 participants) used a total daily aspirin dose of 100 mg or less. Aspirin at a total daily dose of 100 mg or less was associated with reductions in the composite cardiovascular outcome ( 
Exploratory Cancer Outcomes
Incident cancer and cancer mortality were reported in 10 and 12 studies, respectively. There was no significant difference in incident cancer (HR, 1.01 [95% CrI, 0.93-1.08]) or cancer mortality (HR, 1.03 [95% CrI, 0.96-1.11]) with aspirin use compared with no aspirin (Figure 3) . There was evidence of low between-study heterogeneity for incident cancer (I 2 = 14%) and cancer mortality (I 2 = 17%). There was no significant difference in cancer outcomes associated with aspirin in studies in which the risk of the cardiovascular outcome was low (incident cancer: HR, 
Discussion
In this meta-analysis of 13 trials enrolling 164 225 participants without cardiovascular disease, aspirin use was associated with reductions in the composite cardiovascular outcome consisting of cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke. However, aspirin use was associated with an increased risk of major bleeding, intracranial bleeding, and major gastrointestinal bleeding with comparable absolute risk estimates. Aspirin use was associated with reductions in the primary cardiovascular composite outcome and increases in major bleeding risks in both low and high cardiovascular risk populations and in participants with diabetes. Compared with aspirin use in patients with established atherosclerotic cardiovascular disease, aspirin use for primary prevention has been controversial. This uncertainty has been reflected in contradictory guideline recommendations. 8, 9 The current study demonstrates that when considering the totality of evidence, cardiovascular benefits associated with aspirin were modest and equally balanced by major bleeding events. This study builds on previous meta-analyses through the inclusion of 3 studies that enrolled participants for whom uncertainty regarding the efficacy of aspirin for primary prevention existed. The Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) trial enrolled participants with moderate to high estimated cardiovascular risk, the ASCEND trial enrolled participants with diabetes, and the ASPREE trial enrolled older participants (older than 65 or 70 years of age, depending on ethnicity). It has been suggested that patients with substantially increased cardiovascular risk may benefit from preventive aspirin use. 9 The US Preventive Services Task Force recommends the initiation of low-dose aspirin in adults aged 50 to 69 years with a 10-year cardiovascular risk of 10% or more. 9 However, the use of cardiovascular risk scores tends to overestimate an individual's true risk, 32 with poor agreement between different cardiovascular risk calculators. 33 The difference in predicted and observed cardiovascular risk was demonstrated by the ARRIVE trial, in which moderate-risk participants (mean American College of Cardiology/American Heart Association 10-year atherosclerotic cardiovascular disease risk of 17.3%) had an observed event rate of less than 10%. 6 This study showed that when analysis was restricted to populations with observation-derived 10-year cardiovascular event rate estimates of 10% or more, aspirin use was associated with an absolute risk decrease of 0.51% (95% CI, 0.06%-0.93%) for the cardiovascular composite outcome, but an absolute risk increase of 0.64% (95% CI, 0.35%-0.97%) for major bleeding. The challenge of interpreting absolute risk across different outcomes lies in the interpretation of the severity of each outcome. The current study demonstrates that the absolute risk reduction for cardiovascular events and absolute risk increase for major bleeding associated with aspirin use were of similar magnitude. Aspirin use was not associated with a reduction in cardiovascular mortality, and deaths due to bleeding were rare. Consequently, the decision to use aspirin for primary prevention may need to be made on an individual basis, accounting for the patient's risk of bleeding and their views on the balance of risk vs benefit. 34 The role of additional measures to reduce the potential harms of long-term aspirin use is not clear from the present study. Coprescription of aspirin with a proton pump inhibitor (PPI) may limit the risk of significant gastrointestinal bleeding and, therefore, shift the risk-benefit ratio toward an overall benefit of aspirin use for primary prevention in patients without cardiovascular disease. 27 However, the use of PPIs was inconsistently reported in the studies included in this analysis. Furthermore, this strategy has not been adequately tested in RCTs and is of uncertain cost effectiveness.
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The ASPREE study, which enrolled healthy older individuals (median age, 74), demonstrated an increased risk of death in patients randomized to receive aspirin, driven primarily by a 31% increased risk of cancer mortality. 15 This finding is in contrast to an individual patient data meta-analysis of primary and secondary prevention aspirin trials that demonstrated a 15% reduction in cancer mortality associated with aspirin use. 13 While the reduction in cancer mortality emerged after at least 5 years of follow-up, this result was not replicated in the AS-CEND trial that followed up 15 480 participants with diabetes for a mean of 7.4 years. The findings of this study suggest that the association of aspirin with cancer outcomes is neutral, with no suggestion of harm or benefit from the available current evidence. 
Limitations
This study has several limitations. First, the inherent limitations of meta-analyses exist, including the availability and quality of reported data. 35 This was particularly apparent in the diabetes subgroup, in which cardiovascular and bleeding events were poorly reported in studies. Second, end point definitions between trials differed depending on contemporary consensus definitions, reflecting the long timeframe and diagnostic advances encompassed by trials in this study. For the primary cardiovascular outcome, all studies except for AS-CEND defined stroke events as including both ischemic and hemorrhagic etiologies. Post hoc sensitivity analysis excluding ASCEND did not alter the overall findings. Hemorrhagic stroke events could have been included as both a cardiovascular and a bleeding outcome. Third, the total daily doses of aspirin varied in studies from 50 mg to 500 mg, with the majority using doses from 75 mg to 100 mg daily. Doses greater than 100 mg daily are not representative of current clinical practice. Importantly, sensitivity analysis restricted to daily aspirin doses of 100 mg or less demonstrated similar results to the overall analysis, including an increased risk of major bleeding outcomes. Fourth, 8 trials began randomizing study participants over 20 years ago, with 3 trials initiating recruitment in the 1970s and 1980s. 19, 20, 22 Increasing adoption of additional primary prevention strategies, such as risk factor modification and development of public health initiatives, may limit the applicability of earlier studies to current practice. In studies published after 2000, aspirin was associated with reductions in the primary cardiovascular outcome and increases in all bleeding outcomes, but was no longer associated with reduced myocardial infarctions when only more contemporary studies were included.
Conclusions
In this meta-analysis, the use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding. This information may inform discussions with patients about aspirin for primary prevention of cardiovascular events and bleeding. Therefore the search strategy for this systematic review was conducted to update the previous meta-analysis.
The search was undertaken on September, 18 2018.
Search terms were as follows: non-fatal MI and non-fatal stroke) was taken as the major cardiovascular event for which risk was calculated. For each trial, the risk of the primary outcome in the group taking no aspirin was calculated, before being divided by the mean follow-up time (in years) to give the annualised event rate. This was then multiplied by ten to give the 10-year estimated event rate. Confidence intervals were estimated by assuming that events were distributed according to a Poisson distribution.
Bayesian Meta-analysis
For the primary meta-analysis, a Bayesian approach was undertaken using the gemtc package 1 in R (version 3.4.1) 2 and JAGS (version 4.3.0) 3 .
For the frequentist meta-analysis the meta package was used 4 .
Natural logarithms of reported hazard ratios and corresponding standard errors were extracted from studies where available. The number of events and duration of followup (in person-years) were extracted from all other studies, allowing for studies with different lengths of follow-up to be incorporated into the analysis on the hazard ratio scale. This assumes that events occurred at a constant rate during each of these trials.
Fixed-and random-effects models were generated for each outcome using Poisson likelihood and log link using non-informative vague priors 5 . A Markov Chain Monte Carlo (MCMC) approach was used with 5000 adaptation iterations followed by 100,000 iterations of 4 chains. The potential scale reduction factor (PSRF) was used to assess chain convergence, using a cut-off of 1.05 6 .
Heterogeneity was assessed using the I 2 statistic. An I 2 of <25% was considered to represent low heterogeneity, 25-50% moderate heterogeneity, and >50% high heterogeneity.
The Deviance Information Criterion was used to select fixed-or random-effects meta-analysis for each outcome, as has been utilized previously 7 . A difference of greater than 3 units was considered important, and the model with the lowest DIC was used for analysis 8 . Where the DIC was similar between models (within 3 units), model selection was achieved based on heterogeneity in the fixed-effect model, with a random-effects model favored if I 2 >25%.
For the Bayesian meta-analysis 95% credible intervals (CrI) were calculated, and 95% CrI that exclude 1 were treated as statistically significant.
Absolute risk difference (ARD)
For each outcome, the absolute risk in the 'no aspirin' population was calculated as the number of events divided by the total number of participants.
The relative risk and 95% confidence intervals (CI) for each outcome were estimated by random-effects frequentist pairwise meta-analysis using the Mantel-Haenzel method. The relative risk and baseline absolute risk were used to calculate the absolute risk difference with corresponding 95% CI. Negative values indicate a reduction in risk with aspirin treatment and positive values indicate an increased risk.
Numbers needed to treat or harm were calculated for all outcomes with a statistically significant reduction or increase in risk.
Cancer outcomes
Incident cancer (defined as new cancer diagnosis) and cancer mortality were additional exploratory endpoints. Data was extracted on cancer outcomes from studies identified in the primary literature search. Additional related publications providing information on cancer outcomes from included studies were searched on PubMed using the trial name, first or senior author, and the term "cancer". Metaanalyses (both using trial level and individual patient data) were identified, with data extracted from them if they could not be identified from trial publications. Trials were deemed low or high risk if the 10-year cardiovascular risk for the primary cardiovascular outcome was less than 10%, or 10% or more respectively. The Women's Health Study did not report the number of patients in the high cardiovascular risk subgroup; this study was therefore excluded from event rate calculations for participants at high risk of the primary outcome.
